This analysis includes 395 patients with HR+HER2– early-stage breast cancer who participated in I-SPY2 (n = 191 in control and n = 204 from five IO arms: pembrolizumab [n = 40], durvalumab/olaparib [n = 51], pembrolizumab/SD101 [n = 46], cemiplimab [n = 28], and cemiplimab/LAG3 [n = 39]; Fig 1B). This evidence concerns the gene LAG3 and breast carcinoma.